MGMT and glioblastoma: Two studies exploring the different treatment regimes in the elderly (patients aged over 60 years and diagnosed with a GBM): the German Neuro-oncology Group trial, NOA-08 (Wick et al., 2012) and the Nordic study (Malmstrom et al., 2012), also showed that MGMT promoter methylation was both prognostic and predictive for response to alkylating therapy.